调脂治疗 我们何去何从

The intensive statin therapy:how can we do better.

低密度脂蛋白胆固醇(LDL-C)升高是动脉粥样硬化与冠心病的主要危险因素。他汀类药物可以抑制3羟-基-3甲-基戊二酰辅酶A(HMG-CoA)还原酶的活性,显著降低LDL-C,进而降低动脉粥样硬化的发生风险,明显降低冠心病的病死率。本文讨论了应用他汀类药物有关的重要临床研究,探讨了控制LDL-C合理的靶目标、血脂控制与临床收益的关系及调脂治疗的有关问题,对在临床工作中进行合理的调脂治疗有一定的指导意义。

Many clinical trails demonstrated that statin drugs is very effective in the management of atherosclerotic vascular disease,statin drugs can reduce the incidence of the major adverse outcomes of death, heart attack, and stroke. The benefit of statins was due to the lowering of low-density lipoprotein（LDL） cholesterol levels,but there is still much uncertainty in many patient subsets. Nowadays the question is what level of LDL-C is the best for the patients who have a high risk of cardiovascular disease,and how can we do about intensive statin therapy. More evidence is necessary to clarify if current treatment guidelines and low-density lipoprotein cholesterol goals are optimal for all patients within different risk category.